SCHEMBL25409398

SCHEMBL25409398

CC(C(N)=O)[C@@H](N)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.57
SLC1A3 P43003 3/20 0.42
SLC1A2 P43004 3/20 0.42
SLC1A1 P43005 2/20 0.42
TP53 P04637 1/20 0.38
USP2 O75604 1/20 0.34
SLCO1B1 Q9Y6L6 1/20 0.34
ALOX5 P09917 2/20 0.34
GABRP O00591 3/20 0.33
GABRD O14764 3/20 0.33
GABRA1 P14867 3/20 0.33
GABRB1 P18505 3/20 0.33
GABRG2 P18507 3/20 0.33
GABRB3 P28472 3/20 0.33
GABRA5 P31644 3/20 0.33
GABRA3 P34903 3/20 0.33
GABRA2 P47869 3/20 0.33
GABRB2 P47870 3/20 0.33
GABRA4 P48169 3/20 0.33
GABRE P78334 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24425369 1.00 SLC7A5 (0.57) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL1517244 1.00 SLC7A5 (0.57) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL2785642 1.00 SLC7A5 (0.57) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL5322735 0.84 SLC7A5 (0.52) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL5296973 0.84 SLC7A5 (0.52) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL28906024 0.84 SLC7A5 (0.52) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL83870 0.82 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL2266575 0.82 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL9135178 0.82 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1TP53
SCHEMBL4330500 0.82 SLC7A5 (0.63) SLC7A5SLC1A3SLC1A2SLC1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 SLC7A5 86/4885SLC1A3 367/4885SLC1A2 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.